Review Article
Treatment of Elderly Patients with Colorectal Cancer
Table 2
Representative studies of adjuvant chemotherapy for stage II and/or stage III CRC.
| Author (year) | Regimen | DFS | | OS | |
| Moertel (1995) [36] | 5-FU/LEV versus none | 63% versus 47% (3.5 y) | <0.0001 | 71% versus 55% (3.5 y) | 0.0064 | Francini (1994) [37] | 5-FU/LV versus none | 74% versus 59% (5 y) | 0.005 | 79% versus 65% (5 y) | 0.0044 | IMPACT (1995) [38] | 5-FU/LV versus none | 71% versus 62% (3 y) | <0.0001 | 83% versus 78% (3 y) | 0.018 | O’Connell (1997) [39] | 5-FU/LV versus none | 74% versus 58% (5 y) | 0.001 | 74% versus 63% (5 y) | 0.01 | André (2004) [40] | FL + Oxali versus FL | 78% versus 73% (3 y) | 0.002 | – | – | Kuebler (2007) [41] | FLOX versus FULV | 73% versus 67% (4 y) | 0.0034 | – | – | André (2009) [42] | FOLFOX4 versus LV5FU2 | 66% versus 59% (5 y) | 0.005 | 73% versus 69% (6 y) | 0.023 |
|
|
of survival at indicated years in parentheses. y, years; –, not mentioned in the article. |